With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...

This story will be updated Oct. 26 to include detailed Sanovo trial results. | AstraZeneca has offered a detailed look at the ...

TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...

With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

Esteve CDMO, the contract development and manufacturing organization within Spanish specialty pharma Esteve, is overhauling ...

Pfizer’s newest round of workforce cuts may be getting an early start.  | Local news reported Pfizer layoffs in Michigan and North Carolina as the drugmaker kicks of $2.5 billion in planned cost cuts.

This week, the companies announced wins across their late-stage Clarity-1 and Clarity-2 studies of once-daily brepocitinib in ...

Delaying the use of subcutaneous Parkinson’s disease treatments by one year increases annual medical costs by 59.1%, ...

The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium | The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium webpage breached 11 clauses of the U.K ...

Many direct-to-patient (DTP) programs have significantly affected access to medicines, a survey of U.S. | Many direct-to-patient programs have significantly affected access to medicines, a survey of U ...

Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...